-
British Journal of Clinical Pharmacology Jun 19761 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an 80 ng dose of conventional oxprenolol (CO), and after the second of two 80 mg doses of conventional oxprenolol given 12 h apart. Basal pulse rates and blood pressures, and pulse rates before and after a standard exercise test have been compared after the four active treatments and after a placebo. 2 Peak plasma concentrations of oxprenolol attained after 160 mg of the slow release preparation were similar to the peak concentrations after the single 80 mg dose of conventional oxprenolol. Higher concentrations, however, persisted for much longer after the slow release preparations than after the conventional preparations. 3 Neither oxprenolol formulation had any effect on resting pulse rate or blood pressure in normotensive volunteers. 4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Male; Oxprenolol; Physical Exertion; Pulse; Time Factors
PubMed: 788749
DOI: 10.1111/j.1365-2125.1976.tb00619.x -
British Journal of Clinical Pharmacology Mar 19781 Plasma and saliva levels of metoprolol and oxprenolol have been compared in two groups of healthy volunteers. 2 Mean salivary oxprenolol levels were lower than, but... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1 Plasma and saliva levels of metoprolol and oxprenolol have been compared in two groups of healthy volunteers. 2 Mean salivary oxprenolol levels were lower than, but closely related to the corresponding plasma levels (r=0.93), the mean ratio of saliva:plasma concentration being 0.42. 3 Mean salivary metoprolol concentrations were considerably greater thatn the corresponding plasma levels and the relationship between the concentrations in the two fluids was less clear. 4 The evidence presented suggests that oxprenolol diffuses passively whilst metoprolol is actively secreted into saliva. The mechanism involved in the active process is not known.
Topics: Adolescent; Adult; Amylases; Humans; Male; Metoprolol; Oxprenolol; Propanolamines; Saliva; Salivary Proteins and Peptides; Salivation; Time Factors
PubMed: 656265
DOI: 10.1111/j.1365-2125.1978.tb01627.x -
British Journal of Clinical Pharmacology Feb 19781 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction. 2 In patients with "fixed" airways obstruction, neither atenolol nor exprenolol significantly affected airways resistance. 3 In patients with "labile" airways obstruction, atenolol did not produce a significant increase in airways obstruction, whereas oxprenolol did. 4 Following isoprenaline challenge (1500 microgram by inhalation), atenolol permitted full bronchodilatation, whereas oxprenolol almost completely blocked the action of isoprenaline. 5 Partial agonist activity appears to be of less clinical importance than cardioselectivity.
Topics: Adult; Airway Obstruction; Angina Pectoris; Atenolol; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxprenolol; Propanolamines; Respiration; Respiratory Function Tests
PubMed: 339932
DOI: 10.1111/j.1365-2125.1978.tb01608.x -
British Medical Journal Mar 1977
Topics: Emetics; Female; Humans; Middle Aged; Oxprenolol; Sodium Chloride; Suicide
PubMed: 851756
DOI: 10.1136/bmj.1.6064.840-b -
Acta Poloniae Pharmaceutica 2000The kinetics of hydrolysis of octanoyl ester of oxprenolol (O-OXP) and benzoyl ester of oxprenolol (Benz-OXP) has been investigated in aqueous solution at 310 K over the...
The kinetics of hydrolysis of octanoyl ester of oxprenolol (O-OXP) and benzoyl ester of oxprenolol (Benz-OXP) has been investigated in aqueous solution at 310 K over the pH range 0.42-9.5. The decomposition was followed by UV spectral method. At the pH range 0.42 to 9.5, hydrolysis of oxprenolol esters (E-OXP) consists of hydrolysis of BH+ molecules catalyzed by hydrogen ions, spontaneous hydrolysis of BH+ molecules and hydrolysis of BH+ and B molecules catalyzed by hydroxide ions. Various buffer substances were found to exhibit general acid and base catalysis of the degradation.
Topics: Adrenergic beta-Antagonists; Chemical Phenomena; Chemistry, Physical; Colorimetry; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Magnetic Resonance Spectroscopy; Oxprenolol; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet
PubMed: 10846796
DOI: No ID Found -
Journal of the American College of... Nov 1985In 736 patients, 24 hour electrocardiographic recordings were performed 14 to 36 days after acute myocardial infarction before the start of randomized treatment with 320... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
In 736 patients, 24 hour electrocardiographic recordings were performed 14 to 36 days after acute myocardial infarction before the start of randomized treatment with 320 mg of slow release oxprenolol (n = 358) or placebo (n = 378). Follow-up 24 hour electrocardiographic recordings were obtained 5 to 12 days (median 10) and 3, 6 and 12 months after the first administration of the study medication. Oxprenolol-treated patients had a significantly lower daytime heart rate as compared with the placebo group, whereas no difference was found at night. At baseline, 22.1% of the patients allocated to oxprenolol treatment and 29.6% of the placebo group had more than 30 ventricular extrasystoles in 1 hour at least once during 24 hour monitoring; multiform ventricular extrasystoles were present in 58.4 and 62.7%, ventricular couplets in 29.6 and 33.9% and ventricular tachycardia (3 or more consecutive ventricular extrasystoles) in 21.5 and 20.9% of the oxprenolol-treated and placebo-treated patients, respectively. During the 1 year follow-up period, the prevalence of these arrhythmias did not change significantly in either treatment group. There was a trend toward a reduction in the daytime frequency of ventricular couplets in the oxprenolol group. After 3 and 6 months, only multiform ventricular extrasystoles were significantly less frequent in the oxprenolol group than in the placebo group (47.4 and 42.7% versus 59.7 and 57.9%, respectively). Twelve months after the acute event, however, multiform ventricular extrasystole frequency was the same in both groups of patients (52.1 versus 51.0%, respectively). Thus, oxprenolol had a weak suppressant effect on ventricular tachyarrhythmias in survivors of myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Monitoring, Physiologic; Myocardial Infarction; Oxprenolol; Prospective Studies; Random Allocation
PubMed: 2413097
DOI: 10.1016/s0735-1097(85)80295-3 -
British Journal of Clinical Pharmacology 1985The various mechanisms which have been advanced to explain drug absorption are critically reviewed and the limitations of current theories are discussed. Various... (Review)
Review
The various mechanisms which have been advanced to explain drug absorption are critically reviewed and the limitations of current theories are discussed. Various techniques for investigating drug absorption and transit through the gut are presented, and the results obtained with metoprolol are briefly considered to illustrate the potential of some of these methods.
Topics: Body Water; Gastric Emptying; Humans; Intestinal Absorption; Kinetics; Metoprolol; Oxprenolol; Pharmaceutical Preparations
PubMed: 3890912
DOI: 10.1111/j.1365-2125.1985.tb02746.x -
British Medical Journal Jun 1979Fifty-three pregnant women with moderately severe hypertension were randomly allocated to treatment with methyldopa or oxprenolol. There were no significant differences... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Fifty-three pregnant women with moderately severe hypertension were randomly allocated to treatment with methyldopa or oxprenolol. There were no significant differences between the groups in age, height, weight, parity, or stage of gestation at the start of treatment. The outcome of pregnancy was better in the group treated with oxprenolol, with greater maternal plasma volume expansion and placental and fetal growth. No intrauterine deaths occurred in either group, and antepartum fetal distress, detected by oxytocin challenge testing, was evident in only one patient, who received methyldopa. This infant, and one other in the methyldopa group, died in the neonatal period. No neonatal deaths occurred in the oxprenolol-treated group. Even in this small number of patients these results were considerably better than those in untreated women with hypertension of similar severity. Apgar scores in both groups were equivalent at birth, while blood sugar concentrations were higher in the oxprenolol group. Oxprenolol appears to be safe and effective in controlling hypertension during pregnancy. There was no evidence of harmful effects on the fetus, and oxprenolol may offer a selective advantage over methyldopa for fetal growth and wellbeing in utero.
Topics: Adult; Birth Weight; Blood Glucose; Creatinine; Female; Humans; Hypertension; Methyldopa; Oxprenolol; Plasma Volume; Pregnancy; Pregnancy Complications, Cardiovascular; Random Allocation; Uric Acid
PubMed: 466138
DOI: 10.1136/bmj.1.6178.1591 -
British Medical Journal (Clinical... Jun 1983One hundred pregnant women with hypertension (defined as diastolic blood pressure at or above 95 mm Hg) were allocated at random to treatment with methyldopa or... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
One hundred pregnant women with hypertension (defined as diastolic blood pressure at or above 95 mm Hg) were allocated at random to treatment with methyldopa or oxprenolol and were compared with nonhypertensive controls matched according to parity and gestation at delivery. The patients were also stratified into those entering the study early (before 32 weeks' gestation) and those entering late (after 32 weeks' gestation). Although there were no differences in diastolic blood pressure between the hypertensive groups before or during treatment, in the early entry group the systolic blood pressure at entry of those allocated to oxprenolol was significantly higher than that of those receiving methyldopa; this difference remained throughout the treatment period. Also in the early entry group further increments of drug treatment were required to control blood pressure of patients receiving oxprenolol than in those receiving methyldopa. The eventual fetal outcome for all patients treated with methyldopa was the same as that for those treated with oxprenolol; birth weight, placental weight, head circumference, and Apgar score were not significantly different and there were no stillbirths in either group.
Topics: Adult; Birth Weight; Clinical Trials as Topic; Female; Gestational Age; Humans; Hypertension; Methyldopa; Oxprenolol; Pregnancy; Pregnancy Complications, Cardiovascular; Random Allocation
PubMed: 6407638
DOI: 10.1136/bmj.286.6382.1927 -
British Journal of Clinical Pharmacology May 19811 The effects of oxprenolol 80 mg and propranolol 80 mg on resting forearm blood flow (RFBF) and skin temperature were compared in seven normotensive subjects, for 4 h... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1 The effects of oxprenolol 80 mg and propranolol 80 mg on resting forearm blood flow (RFBF) and skin temperature were compared in seven normotensive subjects, for 4 h after an oral dose. 2 There was a significant fall of RFBF after propranolol (mean +/- s.e. mean 0.74 +/- 0.24 ml 100 g-1 min-1) compared to a smaller non-significant reduction after oxprenolol (0.35 +/- 0.19 ml 100 g-1 min-1). Propranolol produced a greater fall in heart rate than oxprenolol at all times except at 2.5 h. Three subjects experienced falls in skin temperature of over 4 degrees C with propranolol. There were no comparable falls after oxprenolol. 3 The results suggest that at the same dose oxprenolol has less effect on RFBF and skin temperature than propranolol.
Topics: Adult; Blood Pressure; Forearm; Heart Rate; Humans; Oxprenolol; Propranolol; Regional Blood Flow; Skin Temperature; Time Factors
PubMed: 7272160
DOI: 10.1111/j.1365-2125.1981.tb01154.x